1047
EFFECT OF SCREENING STRATEGIES ON THE NATURAL HISTORY OF IBD-RELATED AND SPORADIC COLORECTAL CANCER
Date
May 21, 2024
Tracks
Related Products
IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
BACKGROUND Stage II colorectal cancer should undergo adjuvant therapy only in the presence of risk factors and vascular, lymphatic, and perineural invasion (VELIPI) are risk factors for recurrence after surgery…
IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
RANDOMIZED CONTROLLED TRIAL ON ORAL ADMINISTRATION OF LACTOBACILLUS CASEI DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE (MICROBIOTA AND IMMUNE (MICROENVIRONMENT IN POUCHITIS.-MEP1- NCT03136419).
BACKGROUND: Around 20-25% of ulcerative colitis patients undergo restorative proctocolectomy with ileal pouch-anal anastomosis. Pouchitis is an idiopathic inflammatory disease that may occur in ileal pouches, and it can lead to ileal pouch failure…
IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
BACKGROUND: Local excision (LE) with transanal endoscopic microsurgery (TEM) is an established alternative to radical resection in select early rectal cancers and high-risk patients…